首页> 美国卫生研究院文献>Journal of Cancer >Scutellarin induces apoptosis and autophagy in NSCLC cells through ERK1/2 and AKT Signaling Pathways in vitro and in vivo
【2h】

Scutellarin induces apoptosis and autophagy in NSCLC cells through ERK1/2 and AKT Signaling Pathways in vitro and in vivo

机译:黄cut苷通过ERK1 / 2和AKT信号传导途径在体内外诱导NSCLC细胞凋亡和自噬。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Curative molecular therapy for non-small cell lung cancer (NSCLC) is still lacking. Scutellarin, an active flavone extracted from Erigeron breviscapus Hand-Mazz, displays anti-tumor property in diverse cancer types, yet its tumor-suppressive effect on NSCLC is not reported. In this study, we found that scutellarin significantly inhibited the proliferation of NSCLC cells, induced cell apoptosis, and triggered autophagy. Notably, inhibition of autophagy with inhibitor HCQ attenuated the anti-proliferative activity of scutellarin, indicating that scutellarin-induced autophagy is antineoplastic. In addition, HCQ treatment reduced scutellarin-induced apoptosis. Further study demonstrated that scutellarin stimulated phosphorylation of ERK1/2, and inhibition of ERK1/2 with inhibitor U0126 markedly attenuated scutellarin-induced autophagy. Similarly, scutellarin downregulated the expression of p-AKT, and AKT inhibitor MK-2206 induced autophagy. Moreover, there also existed crosstalk between ERK and AKT pathways. Finally, in vivo xenograft nude mice experiment proved that scutellarin treatment significantly reduced tumor growth and increased the levels of LC3-II and p-ERK1/2, suppressed p-AKT in mice tumors. Thus, our study for the first time uncovered the anti-cancer function of scutellarin on NSCLC cells, and might provide a potential novel therapy for treatment of patients with NSCLC.
机译:非小细胞肺癌(NSCLC)的治疗性分子疗法仍然缺乏。黄cut苷(Scutellarin)是从灯盏花灯(Erigeron breviscapus Hand-Mazz)中提取的活性黄酮,在多种癌症类型中均具有抗肿瘤特性,但尚未报道其对NSCLC的抑癌作用。在这项研究中,我们发现黄cut苷显着抑制NSCLC细胞的增殖,诱导细胞凋亡并触发自噬。值得注意的是,用抑制剂HCQ抑制自噬减弱了黄cut素的抗增殖活性,表明黄cut素诱导的自噬是抗肿瘤药。另外,HCQ治疗减少了黄cut苷诱导的细胞凋亡。进一步的研究表明,黄cut素可刺激ERK1 / 2磷酸化,并用抑制剂U0126抑制ERK1 / 2显着减弱黄cut素诱导的自噬。同样,黄素下调了p-AKT的表达,而AKT抑制剂MK-2206诱导了自噬。而且,ERK和AKT途径之间也存在串扰。最后,体内异种移植裸鼠实验证明,黄cut苷处理显着降低了肿瘤的生长并增加了LC3-II和p-ERK1 / 2的水平,抑制了小鼠肿瘤中的p-AKT。因此,我们的研究首次揭示了黄cut苷对NSCLC细胞的抗癌作用,并可能为治疗NSCLC患者提供潜在的新疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号